Replies to post #136197 on Elite Pharmaceuticals Inc (ELTP)

[rdragon]

Because it is horrible and they are hiding bad data and moving forward as fast as they can, and taking shares for salary, and buying shares on the open market.
Oh I see.

[John_Langston]

yes, could be, but if it is so wonderful, why have they not released any of it????

It would just cause the PPS to tank further.

[Couch]

Gee I wonder what data they've given to the FDA. Notice the lack of question mark. No released data this says otherwise. LOL LOL!!!

http://www.elitepharma.com/investor_relations.asp?goto=387

ELITE PHARMACEUTICALS RELEASES POSITIVE TOP LINE HUMAN ABUSE LIABILITY DATA FOR ELI-200, AN OPIOID ABUSE DETERRENT PRODUCT


HAL study compared subjective effects of drug liking, drug high and good drug effects between ELI-200 and the comparator formulation in non-dependent recreational drug users

Northvale, New Jersey, Tuesday, September 09, 2014: Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) today reported top line results from a Human Abuse Liability (HAL) study for the ELI-200 product. ELI-200 is an undisclosed abuse deterrent opioid product for pain.

The study results demonstrated statistically significant (p <.0001) lower measures of drug liking, drug high and good drug effects for Elite’s manipulated (crushed) ELI-200 when compared to the manipulated (crushed) drug listed comparator product and found 91.9% of the subjects experienced increased drug liking with the comparator product compared to ELI-200 in non-dependent recreational drug users when administered intranasally. The study also found 80.6% of the subjects experienced a decrease in drug liking with the intranasal crushed ELI-200 in comparison to the administration of oral intact ELI-200.

The data will be presented at the 16th Annual Rodman and Renshaw Global Investment Conference in New York City on September 9, 2014.